The Disintegration and Dissolution of Nabumetone Dispersible Tablets - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

The Disintegration and Dissolution of Nabumetone Dispersible Tablets
Nabumetone was complexed with β-cyclodextrin, and a 23 factorial design was used to prepare dispersible tablets containing the drug or its complex.The authors analyzed the effects of complexation as well as the levels of ammonium bicarbonate and crospovidone on tablet wetting time (WT), disintegration time (DT), and percent dissolution efficiency at 60 min (%DE60).

Pharmaceutical Technology

Weight uniformity was determined with a digital balance (model 220BL, Shimadzu Corporation, Kyoto, Japan) according to the official method (19). Tablet hardness and thickness were evaluated using a hardness tester (Scientific Engineering Corp., Delhi, India) and digimatic caliper (Mitutoyo Corp., Japan), respectively (20). For each batch, tablet friability was determined in an automated USP friabilator (model EF-2, Electrolab (I) Ltd., Mumbai). Tablet content uniformity was computed from the assay values in 2% w/w solution of sodium lauryl sulphate (9).

In vitro dissolution studies were carried out in triplicate for 45 min in USP dissolution-rate test Apparatus II (model TDT-06T, Electrolab (I) Ltd., Mumbai), as per the official method (9). Dissolution media consisting of 900 mL of 2% w/w SLS in distilled water was maintained at 37 0.5 C and a stirring speed of 50 rpm. Samples were withdrawn at time intervals of 15 min, filtered through 0.45-μm filter, suitably diluted, and analyzed spectrophotometrically at 270 nm using 2% w/w solution of SLS as a reagent blank. Percent dissolution efficiency at 45 min, used to compare the dissolution profiles of the model formulations, was calculated using Equation 2:

in which Yt stands for percent of drug dissolved at time T and Y100 denotes 100 % dissolution (21). The integral representing the area under the dissolution curve between time zero and time T was computed using Graph Pad Prism version 4.02 (GraphPad Software., San Diego, CA).

Regression analysis. The targeted response parameters were statistically analyzed by applying one-way analysis of variance (ANOVA) at 0.05 level in Design-Expert 7.1.3 demo version soft ware (Stat-Ease Inc.., Minneapolis, MN). Individual parameters were evaluated using the F test, and polynomial models of the form indicated in Equation 3 were generated for each response parameter.

in which Y is the level of the measured response, β0 is the intercept, and β1 to β5 are the regression coefficients. X1 and X2 stand for the main effects; X1 X2, X2X3, and X1X3 are the two-way interactions between the main effects, and X1X2X3 represents the three way interaction. Mathematical models containing only the significant terms were generated for each response parameters using multiple linear regression analysis (MLRA) and ANOVA. The models generated were used to construct the three-dimensional graphs in which response parameter Y was represented as a function of X. The effect of independent variables on each response also was visualized from the contour plots.

Validation of the mathematical models. The mathematical models representing the response parameters were validated by developing a new formulation with a combination of factors within the experimental domain (16). Constraints such as minimizing the disintegration time (DT) and maximizing the wetting time (WT)and dissolution efficiency at 60 min (%DE60) were set to locate the optimum settings of the independent variables in the new formulation. The new formulation was evaluated for the responses, and the experimental values obtained were compared with those predicted by the mathematical models.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here